Literature DB >> 25942463

Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role.

Nicole B Carnegie1, Steven M Goodreau, Albert Liu, Eric Vittinghoff, Jorge Sanchez, Javier R Lama, Susan Buchbinder.   

Abstract

BACKGROUND: We aim to identify optimal strategies for deploying pre-exposure prophylaxis among men who have sex with men (MSM) in the United States and Peru to maximize population-level effectiveness in an efficient manner. We use epidemic models to simulate the impact of targeting strategies. Most studies have focused on targeting either the general population or high-risk MSM. Alternative strategies, including serodiscordant couples, may better balance effectiveness and efficiency.
METHODS: We use dynamic stochastic sexual network models based on exponential-family random graph modeling, parameterized from behavioral surveys of MSM in the United States and Peru. These models represent main partnerships and casual contacts separately, permitting modeling of interventions targeting men whose risk derives from combinations of relational types. We also model varying rates of uptake and adherence to pre-exposure prophylaxis (PrEP). We assess sensitivity of results to risk compensation through increases in condomless casual contacts and condomless sex in main partnerships.
RESULTS: Targeting all men who are not exclusively insertive has the largest impact on HIV incidence, but targeting only those with high levels of casual activity yields comparable results using fewer person-years on PrEP. The effect is robust to risk compensation in the United States, but less so in Peru. Targeting serodiscordant main partnerships does not significantly impact incidence, but requires fewer person-years on PrEP per infection averted than other strategies.
CONCLUSIONS: PrEP could be effective in reducing new infections at the population level in both settings. Serodiscordant partnerships are an attractive component of a targeting program, but targeting should include other high-risk men.

Entities:  

Mesh:

Year:  2015        PMID: 25942463      PMCID: PMC4422184          DOI: 10.1097/QAI.0000000000000555

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  44 in total

Review 1.  Preexposure prophylaxis for HIV prevention: where have we been and where are we going?

Authors:  Jared M Baeten; Jessica E Haberer; Albert Y Liu; Nirupama Sista
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07       Impact factor: 3.731

Review 2.  Global epidemiology of HIV infection in men who have sex with men.

Authors:  Chris Beyrer; Stefan D Baral; Frits van Griensven; Steven M Goodreau; Suwat Chariyalertsak; Andrea L Wirtz; Ron Brookmeyer
Journal:  Lancet       Date:  2012-07-20       Impact factor: 79.321

3.  Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

Authors:  Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant
Journal:  Sci Transl Med       Date:  2012-09-12       Impact factor: 17.956

4.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

5.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Kachit Choopanya; Michael Martin; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Praphan Kitisin; Pitinan Natrujirote; Somyot Kittimunkong; Rutt Chuachoowong; Roman J Gvetadze; Janet M McNicholl; Lynn A Paxton; Marcel E Curlin; Craig W Hendrix; Suphak Vanichseni
Journal:  Lancet       Date:  2013-06-13       Impact factor: 79.321

6.  The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study.

Authors:  Gabriela B Gomez; Annick Borquez; Carlos F Caceres; Eddy R Segura; Robert M Grant; Geoff P Garnett; Timothy B Hallett
Journal:  PLoS Med       Date:  2012-10-09       Impact factor: 11.069

7.  Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.

Authors:  Timothy B Hallett; Jared M Baeten; Renee Heffron; Ruanne Barnabas; Guy de Bruyn; Íde Cremin; Sinead Delany; Geoffrey P Garnett; Glenda Gray; Leigh Johnson; James McIntyre; Helen Rees; Connie Celum
Journal:  PLoS Med       Date:  2011-11-15       Impact factor: 11.069

8.  Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance.

Authors:  Virginie Supervie; Meagan Barrett; James S Kahn; Godfrey Musuka; Themba Lebogang Moeti; Lesego Busang; Lesogo Busang; Sally Blower
Journal:  Sci Rep       Date:  2011-12-07       Impact factor: 4.379

9.  What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)?

Authors:  Steven M Goodreau; Nicole B Carnegie; Eric Vittinghoff; Javier R Lama; Jorge Sanchez; Beatriz Grinsztejn; Beryl A Koblin; Kenneth H Mayer; Susan P Buchbinder
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

10.  Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic.

Authors:  Andrew N Phillips; Valentina Cambiano; Fumiyo Nakagawa; Alison E Brown; Fiona Lampe; Alison Rodger; Alec Miners; Jonathan Elford; Graham Hart; Anne M Johnson; Jens Lundgren; Valerie C Delpech
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

View more
  16 in total

1.  Effects of contact network structure on epidemic transmission trees: implications for data required to estimate network structure.

Authors:  Nicole Bohme Carnegie
Journal:  Stat Med       Date:  2017-02-13       Impact factor: 2.373

2.  Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling Study.

Authors:  Samuel M Jenness; Kevin M Weiss; Steven M Goodreau; Thomas Gift; Harrell Chesson; Karen W Hoover; Dawn K Smith; Albert Y Liu; Patrick S Sullivan; Eli S Rosenberg
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

3.  Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States.

Authors:  Samuel M Jenness; Steven M Goodreau; Eli Rosenberg; Emily N Beylerian; Karen W Hoover; Dawn K Smith; Patrick Sullivan
Journal:  J Infect Dis       Date:  2016-07-14       Impact factor: 5.226

4.  Body/Selves and Beyond: Men's Narratives of Sexual Behavior on PrEP.

Authors:  Shana D Hughes; Nicolas Sheon; Erin V W Andrew; Stephanie E Cohen; Susanne Doblecki-Lewis; Albert Y Liu
Journal:  Med Anthropol       Date:  2018-01-19

5.  Barriers to Pre-Exposure Prophylaxis Uptake Among Online Male Sex Workers in the US.

Authors:  Anne E Sundelson; Étienne Meunier; Eric W Schrimshaw; Karolynn Siegel
Journal:  AIDS Behav       Date:  2021-10-27

6.  Concomitant Utilization of Pre-Exposure Prophylaxis (PrEP) and Meningococcal Vaccine (MenACWY) Among Gay, Bisexual, and Other Men Who Have Sex with Men in Los Angeles County, California.

Authors:  Ian W Holloway; Diane Tan; Robert A Bednarczyk; Vincent L Fenimore; Laura Randall; Chelsea S Lutz; Paula M Frew
Journal:  Arch Sex Behav       Date:  2019-10-18

7.  Greater Levels of Self-Reported Adherence to Pre-Exposure Prophylaxis (PrEP) are Associated with Increased Condomless Sex Among Men Who Have Sex with Men.

Authors:  Elizabeth C Pasipanodya; Michael J Li; Sonia Jain; Xiaoying Sun; Jessica Tobin; Eric Ellorin; Michael Dube; Eric S Daar; Katya Corado; Joel Milam; Jill Blumenthal; Sheldon H Morris; David J Moore
Journal:  AIDS Behav       Date:  2020-11

8.  Individual HIV Risk versus Population Impact of Risk Compensation after HIV Preexposure Prophylaxis Initiation among Men Who Have Sex with Men.

Authors:  Samuel M Jenness; Akshay Sharma; Steven M Goodreau; Eli S Rosenberg; Kevin M Weiss; Karen W Hoover; Dawn K Smith; Patrick Sullivan
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

9.  Individual and Network Factors Associated With Racial Disparities in HIV Among Young Men Who Have Sex With Men: Results From the RADAR Cohort Study.

Authors:  Brian Mustanski; Ethan Morgan; Richard DʼAquila; Michelle Birkett; Patrick Janulis; Michael E Newcomb
Journal:  J Acquir Immune Defic Syndr       Date:  2019-01-01       Impact factor: 3.731

10.  The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil.

Authors:  Paula M Luz; Benjamin Osher; Beatriz Grinsztejn; Rachel L Maclean; Elena Losina; Madeline E Stern; Claudio J Struchiner; Robert A Parker; Kenneth A Freedberg; Fabio Mesquita; Rochelle P Walensky; Valdilea G Veloso; A David Paltiel
Journal:  J Int AIDS Soc       Date:  2018-03       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.